Artivion, Inc. $AORT Shares Sold by Royce & Associates LP

Royce & Associates LP lessened its holdings in shares of Artivion, Inc. (NYSE:AORT) by 26.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 529,747 shares of the company’s stock after selling 186,933 shares during the period. Royce & Associates LP’s holdings in Artivion were worth $22,429,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Artivion by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after buying an additional 232,424 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Artivion by 22.8% in the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock valued at $20,062,000 after buying an additional 119,634 shares during the period. Invesco Ltd. boosted its position in shares of Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after acquiring an additional 139,370 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of Artivion by 20.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock worth $11,437,000 after buying an additional 63,205 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Artivion by 0.5% in the 3rd quarter. Principal Financial Group Inc. now owns 259,750 shares of the company’s stock valued at $10,998,000 after purchasing an additional 1,244 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on AORT shares. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Canaccord Genuity Group decreased their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Citizens Jmp upped their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and an average price target of $48.97.

Artivion Trading Up 1.1%

Shares of AORT opened at $38.52 on Monday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $48.25. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 192.58 and a beta of 1.60. The firm has a 50 day simple moving average of $41.93 and a 200-day simple moving average of $43.01.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The business’s revenue was up 19.2% compared to the same quarter last year. Equities analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Lance A. Berry sold 4,485 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $35.69, for a total value of $160,069.65. Following the sale, the executive vice president directly owned 143,965 shares of the company’s stock, valued at approximately $5,138,110.85. This trade represents a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Marshall S. Stanton sold 1,259 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $35.69, for a total transaction of $44,933.71. Following the completion of the sale, the senior vice president owned 41,921 shares of the company’s stock, valued at approximately $1,496,160.49. The trade was a 2.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 104,010 shares of company stock valued at $4,197,721. 8.10% of the stock is currently owned by company insiders.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.